MBX Biosciences 11/7/2024 Earnings Report $11.95 -0.09 (-0.75%) As of 08:54 AM Eastern Earnings HistoryForecast MBX Biosciences EPS ResultsActual EPS-$2.78Consensus EPS -$2.72Beat/MissMissed by -$0.06One Year Ago EPSN/AMBX Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMBX Biosciences Announcement DetailsQuarterDate11/7/2024TimeBefore Market OpensConference Call ResourcesMBX Earnings History MBX Biosciences Earnings HeadlinesWeight-loss drug developer Metsera reveals wider loss in US IPO filingJanuary 11, 2025 | msn.comEarly success for MBX in Phase I trial of GLP-1RA for hypoglycaemiaJanuary 8, 2025 | msn.com24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.January 15, 2025 | Crypto Swap Profits (Ad)MBX Biosciences announces phase 1 topline resuts for MBX 1416January 8, 2025 | markets.businessinsider.comMBX Biosciences' MBX 1416 Shows Positive Phase 1 Data In PBH; Stock Down In Pre-marketJanuary 7, 2025 | markets.businessinsider.comMBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric HypoglycemiaJanuary 7, 2025 | globenewswire.comSee More MBX Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MBX Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MBX Biosciences and other key companies, straight to your email. Email Address About MBX BiosciencesMBX Biosciences (NYSE:MBX), a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.View MBX Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Infosys (1/16/2025)Bank of America (1/16/2025)U.S. Bancorp (1/16/2025)Morgan Stanley (1/16/2025)The PNC Financial Services Group (1/16/2025)Taiwan Semiconductor Manufacturing (1/16/2025)UnitedHealth Group (1/16/2025)Schlumberger (1/17/2025)Truist Financial (1/17/2025)Netflix (1/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
